Langdon L. Miller, MD

home / authors / langdon-l-miller-md

Articles

Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC

Ronald B. Natale, MD;Mark A. Socinski, MD;Alan Sandler, MD;Valerie P. Israel, DO;Langdon L. Miller, MD

July 2nd 2000

This multicenter study enrolled 73 patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC). The study design was based on the hypothesis that the non-overlapping toxicities of a 3-drug

Alternative Dosing Schedules for Irinotecan

Mace L. Rothenberg, MD;John G. Kuhn, PharmD;Larry J. Schaaf, PhD;Ronald L. Drengler, MD;S. Gail Eckhardt, MD;Miguel A. Villalona-calero, MD;Eric K. Rowinsky, MD;Daniel D. Von Hoff, MD;Langdon L. Miller, MD;Rrobert G. Petit, PhD;Lisa Hammond, MD

August 1st 1998

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach